| Name | Title | Contact Details |
|---|
Mazars is an internationally integrated partnership, specialising in audit, accountancy, advisory, tax and legal services*. Operating in over 100 countries and territories around the world, we draw on the expertise of more than 50,000 professionals – 33,000+ in Mazars integrated partnership and 17,000+ via the Mazars North America Alliance – to assist clients of all sizes at every stage in their development. *Where permitted under applicable country laws
Acrisure Re is a leading re/insurance intermediary and corporate advisor/broker dealer, offering bespoke and innovative capital, risk, and program solutions. Our expert multi-disciplinary team leverage their combined experience, market data and leading analytics to provide the very best placement and execution strategies. Operating in Bermuda, Florida, Italy, London, Minnesota, New York, North Carolina, Seattle, Toronto and Zurich, our global team of experienced and talented employees are dedicated to driving a sophisticated, tech-enabled future for the (re)insurance industry.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Yokogawa Electric Corporation is a global leader in measurement, control, and information technologies. Founded in 1915 in Tokyo, Japan, the company began as a small laboratory focused on producing instruments that were primarily imported at the time. Today, Yokogawa operates in 60 countries and employs over 17,365 people, with a significant presence in North America. The company offers a diverse range of products and services, including measurement instruments, advanced control solutions for industrial automation, and information technologies for data management and analysis. Yokogawa serves various industries such as energy, chemicals, pharmaceuticals, and food, helping clients tackle complex production and operations management challenges. Their commitment to quality, innovation, and societal contribution guides their operations and partnerships with customers.
Atlas Battery Limited was incorporated as a public limited Company on October 19, 1966 and its shares are listed on Karachi and Lahore Stock Exchanges in Pakistan. The Company is engaged in manufacture and sales of AGS brand, automotive and motorcycle batteries. The Company has joint venture with GS Yuasa International. Atlas Battery Limited pioneered the manufacture of dry charged Hard Rubber batteries in Pakistan. The company has always been at the vanguard of development in the automotive industry in Pakistan making great strides in the fields research and development. The brand has, over the years, earned a solid reputation as a product of latest Japanese technology with consistently high levels of performance and reliability.